Vaccine (Peptide vaccine) · Immune activation, directed at influenza A virus hemagglutinin and influenza B virus hemagglutinin · developed by Novavax
Fluzone HD is a trivalent inactivated influenza vaccine containing 60 µg per strain of three influenza strains.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06482359 | Phase 2/3 | COVID-19 | Withdrawn | NVAX |
| NCT03293498 | Phase 1/2 | Influenza | Completed | NVAX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
COVID-19Influenza
Updated Oct 3, 2026. Something wrong or missing? Report it on the NVAX page.
See NVAX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NVAX catalysts and pipeline →